Kornimate/medical-research-clean huggingface dataset:
electrical stimulation for vision neuroenhancement in glaucoma

Conditions: Glaucoma; Glaucoma Open-Angle

Summary: the purpose of the study is to evaluate the efficacy, transorbital alternating current stimulation (rtacs) using the eyetronic for the treatment in patients with glaucoma.


Eligibility criteria:
inclusion criteria: * participant must be at least 18. * participant must has the ability to comply with the requirements of the study and complete the schedule of events (soe). * participant's clinical diagnosis must be consistent with normal tension glaucoma characterized by the following features: mean deviation (md) worse than -6 but better than -20 on reliable humphrey visual field 24-2 testing * participant's eye pressure must be clinically stable, with iop \< 18. * if a participant has two eyes meeting study criteria, the worse eye as determined by visual field index (vfi) or patient preference, will be deemed includable. if both eyes qualify and have the same vfi, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study. * participant must understand and sign the informed consent. if the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety. exclusion criteria: * participant is unable to comply with study procedures or follow-up visits. * participant has a history of ocular herpes zoster. * participant has a requirement of acyclovir and/or related products during study duration. to be eligible for this study, the participant must discontinue use of these products prior to enrollment and must not continue with the products until after they have completed the study. * participant has evidence of corneal opacification or lack of optical clarity. * participant has uveitis or other ocular inflammatory disease. * participant is receiving systemic steroids or other immunosuppressive medications. * participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration. * participant is pregnant or lactating. * participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. * patients with opened skull, after trepanation or with heart and brain pacemaker. * patients with implanted intracranial metals such as clippings, coilings, ventriculo-peritoneal shunts, endoprosthesis etc. * patients with any skin damage in the area of electrode placement. * children and comatose patients. * patients with recent history of epileptic seizure. * patients with uncontrolled high levels of blood pressure (\<160 mmhg) or uncontrolled high levels of intraocular pressure (\<27 mmhg). * patients abusing drugs or alcohol.

Keywords: glaucoma open-angle glaucoma
episcleral dexamethasone for treatment of macular edema and inflammatory disorders of the posterior pole

Conditions: Macular Edema; Radiation Retinopathy; Branch Retinal Vein Occlusion; Epiretinal Membrane; Central Serous Retinopathy With Pit of Optic Disc; Commotio Retinae; Vitritis

Summary: this phase i trial will assess primarily the safety and secondarily anti-inflammatory effect of episcleral dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous.

this phase i trial will assess primarily the safety and secondarily anti-inflammatory effect of episcleral dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous. numerous studies have documented the anti-inflammatory activity of dexamethasone in macular edema associated with diabetes, branch retinal vein occlusion, and non-infectious posterior uveitis. the investigators hypothesize that episcleral dexamethasone is safe, tolerable and that its anti-inflammatory activity will interface with the pro-inflammatory cascade associated with macular edema due to diabetes, surgery, trauma, vein occlusions, uveitis and retinal degeneration to improve visual structure and function. the investigators hypothesize that episcleral dexamethasone is safe, tolerable and that its anti-inflammatory activity will reduce macular edema and improve vision. the investigator's objective is to primarily assess the safety, tolerability and pharmacokinetics of episcleral dexamethasone in patients with macular edema; to secondarily assess efficacy in reducing macular edema and improving visual structure and function. the main outcome of the study is safety assessment. secondary outcomes are assessment of visual acuity and anatomical changes in the macula as measured via optical coherence tomography (oct) and fluorescein angiogram.

Eligibility criteria:
inclusion criteria: * age \>= 18 years; * visual acuity letter score in study eye \< 70 and ≥ 25 letters (approximate snellen equivalent 20/32 to 20/320); * ophthalmoscopic evidence of center-involved macular edema, within the central subfield (csf); * inflammatory disorders of the sclera, choroid, retina or vitreous exclusion criteria: * inability to understand informed consent, cooperate with testing or return to follow up visits; * pregnant or lactating women; * co-existent ocular disorder of the cornea, lens or media that will interfere with assessment of safety or efficacy.

Keywords: macular edema radiation retinopathy branch retinal vein occlusion epiretinal membrane central serous retinopathy with pit of optic disc commotio retinae vitritis
oral health, microbial burden and covid-19

Conditions: Covid19; Periodontitis

Summary: an observational study of patients with covid-19 confirmed cases (with various degrees of severity) and controls. oral and nasal swabs will be taken from 150 patients (50 with mild form and 50 with severe form of covid-19 with or without mechanical ventilation, 50 healthy controls).


Eligibility criteria:
inclusion criteria: 1. must provide written informed consent 2. subjects have to be tested (pcr) positive or negative for sars-cov2 infection 3. must be able to provide oral and nasal swabbing within 48 hours of polymerise chain reaction (pcr) test results exclusion criteria: a. under the age of 18 years old

Keywords: covid-19 human microbiome oral microbiome sars-cov-2 infection
the role of parents in adolescent weight loss

Conditions: Adolescent Obesity

Summary: the purpose of the study is to determine whether a novel model of including parents in adolescent weight control results in greater decrease in adolescent z-bmi compared to an intervention with minimal parent involvement.


Eligibility criteria:
inclusion criteria: * between 30 and 90% overweight * parent or guardian willing to participate exclusion criteria: * major psychiatric disorder
s-1 combined cisplatin hipec for palliative operation gastric cancer of stage iv limited peritoneal metastasis

Conditions: Stage IV Gastric Cancer

Summary: this study is designed to investigate the efficacy of s-1 plus cisplatin hyperthermic intraperitoneal chemotherapy for advanced gastric patients of gastric cytoreductive surgery (crs)

this project is a single-center, open clinical observation the safety and efficacy that stage iv limited peritoneal metastasis of gastric cancer patients accept s-1 plus hyperthermic intraperitoneal chemotherapy . with advanced gastric patients of confined to the peritoneal after crs as the research object, with progression-free survival and overall survival, adverse events as the end points.

Eligibility criteria:
inclusion criteria: * 18 ≤ age ≤ 70 years old * patients with histologically confirmed gastric cancer (adenocarcinoma), stage iv (limited to the abdominal cavity), accpeted palliative cytoreductive surgery and no prior chemotherapy, biological therapy or targeted anti-cancer therapy, etc. * the eastern cooperative oncology group (ecog) status ≤ 2 * having given written informed consent prior to any procedure related to the study * expected survival time ≥3 months exclusion criteria: * known to have abdominal viscera metastasis of gastric cancer patients * inadequate hematopoietic function which is defined as below: * white blood cell (wbc) less than 3,500/mm\^3 * absolute neutrophil count (anc) less than 1,500/mm\^3 * platelets less than 80,000/mm\^3 * inadequate hepatic or renal function which is defined as below: * serum bilirubin greater than 2 times the upper limit of normal range * alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 2.5 times the uln if no demonstrable liver metastases or greater than 5 times the uln in the presence of liver metastases * blood creatinine level greater than 1.5 times uln,creatinine clearance \< 60ml/min * receiving a concomitant treatment with other fluoropyrimidine drug or flucytosine drug * women who is pregnant or lactating or fertile women of child-bearing potential unless using a reliable and appropriate contraceptive method throughout the treatment period (including male) * psychiatric disorder or symptom that makes participation of the patient difficult * myocardial infarction, existing serious or unstable angina, and patients with cardiac insufficiency in 6 months * severe complication(s), e.g., paresis of intestines, ileus, radiographically confirmed interstitial pneumonitis or pulmonary fibrosis, glomerulonephritis ,renal failure, poorly-controlled diabetes * known dpd deficiency * have the history of allograft transplantation * conducted the autologous bone marrow transplantation in 4 weeks * participate in other clinical trial before the start of this trial in 4 weeks * patient compliance is bad or researchers believe that patients are not suitable for this treatment * known to have active hepatitis patients * her-2-positive patients (ich3+or fish+) * history of severe hypersensitivity reactions to the ingredients of s-1 or cisplatin
efficacy of a depigmented extract of phleum in local allergic rhinitis

Conditions: Allergic Rhinitis

Summary: the purpose of this study is evaluate the efficacy of a depigmented grass extract in the treatment of local allergic rhinitis.


Eligibility criteria:
inclusion criteria: * local allergic rhinitis with sensitization to grass pollen * skin prick test and serum specific ige negative to grass pollen. * positive nasal allergen provocation test (napt) to grass pollen and/or positive nasal specific ige to grass pollen. * written informed consent exclusion criteria: * immunological diseases * heart diseases that limit the use of adrenaline. for example, severe hypertension or treatment with beta-blockers. * treatment with beta-blockers * severe psychological disorders * severe atopic dermatitis * fev1 \< 70% of reference value after treatment * hypersensitivity or intolerance to excipients and / or medication trial. * failure to adequately perform diagnostic tests or treatment. * sensitization to other allergens (perennial or seasonal) with clinical relevance for the subject and that may interfere in the evaluation of the response. * immunotherapy in the 5 years prior to their inclusion in the study. * pregnant women or at risk of pregnancy and lactating women.
oxford uka and hto post-market clinical study

Conditions: Knee Osteoarthritis

Summary: the purpose of this study is to compare the performance and safety of medial uka and hto in the treatment of amoa in term of functional outcome, radiographic assessment, range of motion, postoperative complications, revision rate and relevant health economics outcome.

the purpose of this study is to compare the outcomes of medial uka and hto in the treatment of amoa by investigating the performance of these 2 procedures in terms of functional outcome, radiographic assessment, range of motion, postoperative complications, revision rate and relevant health economics outcome, then identify factors associated with better clinical performance. it is aimed to provide evidence-based guidelines for selecting the appropriate procedure in managing amoa in chinese population based on the findings of this study. the secondary endpoints will include: 1. pain numerical rating scale (nrs) 2. sf-12 health survey 3. radiographic assessment includes pre-op and post-op mechanical femorotibial angle (mfta), patella height, patellofemoral medial and lateral articular surfaces, and displacement angle of patella 4. range of motion 5. adverse event rate and classification (including complication) 6. operating time 7. total blood loss (brecher formula) 8. revision rate health economic outcomes based on hospital discharge days, recovery time, physiotherapy and complications/ reoperations will also be analyzed.

Eligibility criteria:
inclusion criteria: 1. patient is aged 18 to 85 years old, inclusive; 2. patients who diagnosed with amoa of the knee, and have undergone open wedge hto, or primary unilateral partial knee arthroplasty with oxford partial knee with microplasty® instrumentation in accordance to indications of uka and the following radiographic assessments in the knee joint: * exposed bone on both the femur and tibia in the medial compartment. * functionally intact acl * full thickness lateral cartilage (ignore osteophytes) * functionally normal mcl: correctable deformity (normal medial opening) * acceptable patellofemoral joint: normal, medial facet oa with or without bone loss, lateral facet oa without bone loss. 3. uka or hto procedure completed one year prior to study participation; 4. patient provides written informed consent by signing and dating the institutional review board/ethics committee (irb/ec) approved informed consent form. exclusion criteria: 1. has undergone uka but met any of the contraindications included in the product labeling of oxford partial knee system; 2. has rheumatoid arthritis or other forms of inflammatory joint disease; 3. uncooperative or with neurologic disorders who are incapable of following directions; 4. has a diagnosed systemic disease that could affect his/her safety or the study outcome; 5. anterior cruciate ligament and posterior cruciate ligament injury, collateral ligament instability; 6. known to be pregnant; 7. prisoner or known alcohol / drug abuser.

Keywords: anteromedial osteoarthritis (amoa)
probiotics and health-related quality of life in individuals with seasonal allergies

Conditions: Healthy

Summary: in this randomized, double-blind, placebo-controlled study, participants with seasonal allergies will receive a daily probiotic or placebo for 8 weeks. questionnaires will assess health-related quality of life, stress, physical activity, gastrointestinal symptoms, adverse events, and compliance. in a subset of subjects, stool and blood samples will be collected at baseline and at week 6 of the intervention (estimated to be peak allergy season) to characterize microbial communities and immune function.


Eligibility criteria:
inclusion criteria: subjects will be included if they: * are 18 to 60 years of age (inclusive). * receive a score of 2 or greater on the mini rhinoconjunctivitis quality of life questionnaire. * are willing and able to complete the informed consent form in english. * are available for 8 consecutive weeks to participate in this study. * be willing and able to complete online daily and weekly questionnaires regarding general wellness, bowel function, quality of life, gastrointestinal symptoms, and physical activity. * are willing and able to maintain their regular level of physical activity and diet for the 8-week study. * are able to take the study supplement without the aid of another person. * are willing to discontinue consumption of fermented foods or probiotics (e.g., yogurts with live, active cultures or supplements), or immune-enhancing supplements (e.g., echinacea or fish oil). * are willing to provide 2 blood and 2 stool samples (subgroup only). exclusion criteria: subjects will be excluded if they: * do not meet any of the above criteria. * use allergy medications, including nasal sprays, 5 or more days per week. * receive allergy shots. * are currently pregnant or attempting to get pregnant. * are currently taking any systemic corticosteroids, androgens (such as testosterone), or large doses of anti-inflammatory drugs (i.e., aspirin in doses \>600 mg/d) on a regular basis. * are currently being treated for or have any of the following physician-diagnosed diseases or conditions: hiv/aids; immune modulating diseases (autoimmune disease, hepatitis, cancer, etc.); kidney disease; pancreatitis; pulmonary disease; hepatic or biliary disease; or gastrointestinal diseases/conditions such as diverticulitis, ulcerative colitis, crohn's disease, celiac disease, short bowel disease, ileostomy, or colostomy, but not including gerd; or have a central venous catheter. * have received chemotherapy or other immune suppressing therapy within the last year.

Keywords: probiotic allergy immune
brief prolonged exposure therapy versus clinical standard to reduce posttraumatic stress post spinal cord injury

Conditions: Spinal Cord Injuries; PTSD; Post-Traumatic Stress Disorder

Summary: this study will examine the use brief prolonged exposure (brief pe) therapy compared to standard clinical care to reduce posttraumatic distress among people who have had a spinal cord injury and are receiving rehabilitation in an inpatient setting.

this is a prospective randomized controlled trial examining the efficacy of brief prolonged exposure therapy (brief pe) delivered in an inpatient rehabilitation setting post-sci to reduce ptsd symptoms. the overall goal of this project is to test a brief pe (three 60-minute sessions) to reduce psychological distress after sci and to mitigate long-term post-sci distress including ptsd as well as secondary health outcomes (including depression and general anxiety) at 1, 3, and 6 months from baseline. the intervention group (brief pe) will be compared to standard clinical care with treatment as usual (tau).

Eligibility criteria:
inclusion criteria: * 18 years of age or older * admitted to the inpatient rehabilitation hospital diagnosed with a sci following a traumatic event exclusion criteria: * patients in police custody * not fluent in the english language * severe cognitive impairment * patients who are acutely suicidal * patients with active psychosis

Keywords: ptsd sci spinal cord injury post-traumatic stress disorder
bimatoprost 0.03% versus travoprost 0.004% in patients currently on latanoprost 0.005%

Conditions: Glaucoma; Ocular Hypertension

Summary: patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional iop lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%


Eligibility criteria:
inclusion criteria: * glaucoma or ocular hypertension in both eyes * currently being treated with latanoprost 0.005% daily and in need of additional iop-lowering * best-corrected visual acuity of 20/100 or better in each eye * visual field within 6 months of study entry exclusion criteria: * secondary glaucoma * active intraocular inflammation or macular edema * intraocular surgery or laser surgery within the past 3 months
intense pulse light treatment with meibomian gland expression of the upper eyelids in dry eye disease

Conditions: Dry Eye

Summary: upper eyelid treatment has not been used with previously described methods of treatment of dry eye disease using intense pulsed light therapy because the upper lids disease was typically not as advanced as lower lid and because direct treatment of the upper lid was not felt to be necessary as each light pulse extended over the entire periorbita even when concentrated on the lower lid.

dry eye disease is an under-diagnosed and growing problem. intense pulsed light has been a proven method of improving the signs and symptoms of meibomian gland dysfunction including lid margin vascularity, meibum viscosity, osdi mean score and tear break up. this study looks at the safety and effect of treatment of upper lids only to evaluate the safety and efficacy of direct upper lid treatment on the signs and symptoms of dry eye.

Eligibility criteria:
inclusion criteria: * subjects older than 18 * cloudy or inspissated meibomian glands in both upper lids * ocular pain due to dry eye unrelieved by current or prior use of conservative topical dry eye medications including but not limited to over the counter artificial tears, lifitegrast, cyclosporine, or sodium chloride. exclusion criteria: * patients with eyelid abnormalities * intense pulsed light treatment within the past year. * patients on oral retinoids, * patients undergoing intraocular surgery within the past year, * patients with uncontrolled ocular disease, * fitzpatrick skin type v or vi, * neuro-paralysis in the planned treatment area in the past 6 months, * pre-cancerous lesions in the planned treatment area. * new topical eye treatments, * previous expression of meibomian glands, * legally blind in one eye.

Keywords: meibomian gland dysfunction
phase i chinese pk

Conditions: Advanced Solid, Malignant Tumors

Summary: an open, phase 1 to assess the pk of rising doses of zd6474 when administered daily in chinese patients with advanced solid malignant tumors.


Eligibility criteria:
inclusion criteria: * histological and/or cytological confirmation of a malignant solid tumor * refractory to standard therapies or for which no appropriate therapies exist * who performance status 0-2 exclusion criteria: * patients with brain tumors or symptomatic cerebral metastases * systemic anticancer therapy within the last 4 weeks

Keywords: zd6474 pk